Johnson & Johnson ROE 2010-2024 | JNJ
Current and historical return on equity (ROE) values for Johnson & Johnson (JNJ) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Johnson & Johnson ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2024-03-31 |
$40.58B |
|
75.00% |
| 2023-12-31 |
$35.15B |
$68.77B |
48.95% |
| 2023-09-30 |
$34.62B |
$71.23B |
46.90% |
| 2023-06-30 |
$13.05B |
$76.41B |
17.48% |
| 2023-03-31 |
$12.72B |
$70.87B |
17.04% |
| 2022-12-31 |
$17.94B |
$76.80B |
23.73% |
| 2022-09-30 |
$19.16B |
$74.60B |
25.57% |
| 2022-06-30 |
$18.37B |
$76.36B |
24.87% |
| 2022-03-31 |
$19.83B |
$74.71B |
27.49% |
| 2021-12-31 |
$20.88B |
$74.02B |
29.86% |
| 2021-09-30 |
$17.88B |
$70.27B |
26.59% |
| 2021-06-30 |
$17.77B |
$69.58B |
27.01% |
| 2021-03-31 |
$15.12B |
$65.83B |
23.57% |
| 2020-12-31 |
$14.71B |
$63.28B |
23.35% |
| 2020-09-30 |
$16.99B |
$64.47B |
27.37% |
| 2020-06-30 |
$15.19B |
$62.98B |
25.10% |
| 2020-03-31 |
$17.17B |
$61.29B |
28.64% |
| 2019-12-31 |
$15.12B |
$59.47B |
25.47% |
| 2019-09-30 |
$14.15B |
$58.21B |
23.81% |
| 2019-06-30 |
$16.33B |
$60.79B |
26.76% |
| 2019-03-31 |
$14.68B |
$58.96B |
23.85% |
| 2018-12-31 |
$15.30B |
$59.75B |
24.42% |
| 2018-09-30 |
$1.54B |
$64.63B |
2.46% |
| 2018-06-30 |
$1.37B |
$62.89B |
2.11% |
| 2018-03-31 |
$1.25B |
$63.26B |
1.85% |
| 2017-12-31 |
$1.30B |
$60.16B |
1.88% |
| 2017-09-30 |
$15.83B |
$73.98B |
22.08% |
| 2017-06-30 |
$16.34B |
$71.92B |
22.89% |
| 2017-03-31 |
$16.51B |
$70.34B |
23.08% |
| 2016-12-31 |
$16.54B |
$70.42B |
22.95% |
| 2016-09-30 |
$15.94B |
$72.77B |
22.06% |
| 2016-06-30 |
$15.03B |
$72.47B |
20.88% |
| 2016-03-31 |
$15.55B |
$72.65B |
21.71% |
| 2015-12-31 |
$15.41B |
$71.15B |
21.88% |
| 2015-09-30 |
$14.72B |
$71.55B |
21.00% |
| 2015-06-30 |
$16.11B |
$71.13B |
22.58% |
| 2015-03-31 |
$15.92B |
$67.88B |
21.78% |
| 2014-12-31 |
$16.32B |
$69.75B |
21.69% |
| 2014-09-30 |
$17.32B |
$76.59B |
22.70% |
| 2014-06-30 |
$15.55B |
$78.05B |
20.84% |
| 2014-03-31 |
$15.06B |
$76.58B |
20.77% |
| 2013-12-31 |
$13.83B |
$74.05B |
19.73% |
| 2013-09-30 |
$12.88B |
$69.80B |
19.00% |
| 2013-06-30 |
$12.87B |
$69.67B |
19.41% |
| 2013-03-31 |
$10.44B |
$66.86B |
16.32% |
| 2012-12-31 |
$10.85B |
$64.83B |
17.34% |
| 2012-09-30 |
$8.50B |
$63.76B |
14.02% |
| 2012-06-30 |
$8.74B |
$60.43B |
14.54% |
| 2012-03-31 |
$10.11B |
$61.37B |
16.70% |
| 2011-12-31 |
$9.67B |
$57.08B |
16.08% |
| 2011-09-30 |
$11.40B |
$61.53B |
18.99% |
| 2011-06-30 |
$11.61B |
$62.13B |
19.69% |
| 2011-03-31 |
$12.28B |
$59.86B |
21.69% |
| 2010-12-31 |
$13.33B |
$56.58B |
24.28% |
| 2010-09-30 |
$13.60B |
$57.29B |
25.46% |
| 2010-06-30 |
$13.53B |
$52.85B |
26.17% |
| 2010-03-31 |
$13.29B |
$52.91B |
26.55% |
| 2009-12-31 |
$12.27B |
$50.59B |
25.69% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$360.407B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
